{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T04:35:27Z","timestamp":1784349327016,"version":"3.55.0"},"reference-count":91,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"am","delay-in-days":397,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"publisher","award":["R01HL139963"],"award-info":[{"award-number":["R01HL139963"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","heartlungcirc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart, Lung and Circulation"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.hlc.2023.02.011","type":"journal-article","created":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T02:34:54Z","timestamp":1681180494000},"page":"780-789","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Barriers in Heart Failure Gene Therapy and Approaches to Overcome Them"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3505-495X","authenticated-orcid":false,"given":"Anjali J.","family":"Ravichandran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1261-5785","authenticated-orcid":false,"given":"Francisco J.","family":"Romeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6700-3781","authenticated-orcid":false,"given":"Renata","family":"Mazurek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8287-3483","authenticated-orcid":false,"given":"Kiyotake","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hlc.2023.02.011_bib1","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1056\/NEJMsa0803563","article-title":"Rehospitalizations among patients in the Medicare fee-for-service program","volume":"360","author":"Jencks","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hlc.2023.02.011_bib2","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1001\/jama.2009.1180","article-title":"Heart failure performance measures and outcomes: real or illusory gains","volume":"302","author":"Fonarow","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.hlc.2023.02.011_bib3","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1161\/CIR.0000000000000950","article-title":"American Heart Association Council on Epidemiology, Prevention Statistics Committee and Stroke Statistics SubcommitteeHeart Disease and Stroke Statistics-2021 Update: A Report from the American Heart Association","volume":"143","author":"Virani","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2023.02.011_bib4","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology","volume":"118","author":"Savarese","year":"2023","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.hlc.2023.02.011_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107967","article-title":"Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination","volume":"230","author":"Yu","year":"2022","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.hlc.2023.02.011_bib6","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1124\/jpet.122.001234","article-title":"RNAi-based therapeutics and novel RNA bioengineering technologies","volume":"384","author":"Traber","year":"2023","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.hlc.2023.02.011_bib7","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s42466-021-00162-9","article-title":"Therapy development for spinal muscular atrophy: perspectives for muscular dystrophies and neurodegenerative disorders","volume":"4","author":"Jablonka","year":"2022","journal-title":"Neurol Res Pract"},{"key":"10.1016\/j.hlc.2023.02.011_bib8","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.ophtha.2019.06.017","article-title":"Efficacy, safety, and durability of voretigene neparvovec-rzyl in RPE65 mutation-associated inherited retinal dystrophy: results of Phase 1 and 3 trials","volume":"126","author":"Maguire","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.hlc.2023.02.011_bib9","article-title":"Stable and durable factor IX levels in hemophilia B patients over 3\u00a0years\u00a0post etranacogene dezaparvovec gene therapy","author":"von Drygalski","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.hlc.2023.02.011_bib10","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1200\/JCO.22.00343","article-title":"Randomized, double-blind, placebo-controlled, global Phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma","volume":"41","author":"Chesney","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hlc.2023.02.011_bib11","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/imj.15880","article-title":"Approved gene therapies in Australia: coming to a store near you","volume":"52","author":"Mallik","year":"2022","journal-title":"Intern Med J"},{"key":"10.1016\/j.hlc.2023.02.011_bib12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1161\/CIRCRESAHA.116.310039","article-title":"Introducing genes to the heart: all about delivery","volume":"120","author":"Hajjar","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.hlc.2023.02.011_bib13","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/S0140-6736(16)00082-9","article-title":"Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial","volume":"387","author":"Greenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.hlc.2023.02.011_bib14","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/s41434-020-0171-7","article-title":"Investigation of the safety and feasibility of AAV1\/SERCA2a gene transfer in patients with chronic heart failure supported with a left ventricular assist device - the SERCA-LVAD TRIAL","volume":"27","author":"Lyon","year":"2020","journal-title":"Gene Ther"},{"key":"10.1016\/j.hlc.2023.02.011_bib15","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1093\/eurheartj\/ehw019","article-title":"Gene therapy for the treatment of heart failure: promise postponed","volume":"37","author":"Hulot","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hlc.2023.02.011_bib16","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.111.022889","volume":"124","author":"Jessup","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2023.02.011_bib17","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1002\/ejhf.826","article-title":"AGENT-HF Investigators.Effect of intracoronary administration of AAV1\/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure: results from the AGENT-HF randomized phase 2 trial","volume":"19","author":"Hulot","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hlc.2023.02.011_bib18","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jamacardio.2016.0008","article-title":"Intracoronary gene transfer of adenylyl cyclase 6 in patients with heart failure: a randomized clinical trial","volume":"1","author":"Hammond","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.hlc.2023.02.011_bib19","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/eurheartj\/ehaa898","article-title":"Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study","volume":"42","author":"T\u00e4ubel","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hlc.2023.02.011_bib20","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ahj.2018.04.005","article-title":"Design of a Phase 3 trial of intracoronary administration of human adenovirus 5 encoding human adenylyl cyclase type 6 (RT-100) gene transfer in patients with heart failure with reduced left ventricular ejection fraction: The FLOURISH Clinical Trial","volume":"201","author":"Penny","year":"2018","journal-title":"Am Heart J"},{"key":"10.1016\/j.hlc.2023.02.011_bib21","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1093\/eurheartj\/ehv254","article-title":"Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial","volume":"36","author":"Chung","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hlc.2023.02.011_bib22","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s40291-022-00632-z","article-title":"Progress in clinical gene therapy for cardiac disorders","volume":"27","author":"Romeo","year":"2023","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.hlc.2023.02.011_bib23","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.hlc.2023.02.011_bib24","first-page":"GE01","article-title":"Non viral vectors in gene therapy\u2014an overview","volume":"9","author":"Ramamoorth","year":"2015","journal-title":"J\u00a0Clin Diagn Res"},{"key":"10.1016\/j.hlc.2023.02.011_bib25","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.hlc.2023.02.011_bib26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ymeth.2017.10.008","article-title":"Design, assembly, production, and transfection of synthetic modified mRNA","volume":"133","author":"Oh","year":"2018","journal-title":"Methods"},{"key":"10.1016\/j.hlc.2023.02.011_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112385","article-title":"Chemically modified mRNA beyond COVID-19: Potential preventive and therapeutic applications for targeting chronic diseases","volume":"145","author":"Elkhalifa","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.hlc.2023.02.011_bib28","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3390\/pharmaceutics12020102","article-title":"Opportunities and challenges in the delivery of mRNA-based vaccines","volume":"12","author":"Wadhwa","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.hlc.2023.02.011_bib29","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41573-021-00355-6","article-title":"VEGFA mRNA for regenerative treatment of heart failure","volume":"21","author":"Collen","year":"2022","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"10.1016\/j.hlc.2023.02.011_bib30","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.ymthe.2022.11.017","article-title":"Direct intramyocardial injection of VEGF mRNA in patients undergoing coronary artery bypass grafting","volume":"31","author":"Anttila","year":"2023","journal-title":"Mol Ther"},{"key":"10.1016\/j.hlc.2023.02.011_bib31","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41467-020-14349-2","article-title":"Preclinical development of a miR-132 inhibitor for heart failure treatment","volume":"11","author":"Foinquinos","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.hlc.2023.02.011_bib32","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/eurheartj\/ehaa791","article-title":"CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure","volume":"42","author":"Batkai","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hlc.2023.02.011_bib33","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1021\/mp5006239","article-title":"Synthetic chemically modified mrna-based delivery of cytoprotective factor promotes early cardiomyocyte survival post-acute myocardial infarction","volume":"12","author":"Huang","year":"2015","journal-title":"Mol Pharm"},{"key":"10.1016\/j.hlc.2023.02.011_bib34","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1161\/CIRCULATIONAHA.119.041882","article-title":"Altering sphingolipid metabolism attenuates cell death and inflammatory response after myocardial infarction","volume":"141","author":"Hadas","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2023.02.011_bib35","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3390\/cells10010187","article-title":"mRNA-enhanced cell therapy and cardiovascular regeneration","volume":"10","author":"Chanda","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.hlc.2023.02.011_bib36","doi-asserted-by":"crossref","first-page":"565","DOI":"10.5483\/BMBRep.2020.53.11.185","article-title":"Helper virus-free gutless adenovirus (HF-GLAd): a new platform for gene therapy","volume":"53","author":"Liu","year":"2020","journal-title":"BMB Rep"},{"key":"10.1016\/j.hlc.2023.02.011_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0299-y","article-title":"No more helper adenovirus: production of gutless adenovirus (GLAd) free of adenovirus and replication-competent adenovirus (RCA) contaminants","volume":"51","author":"Lee","year":"2019","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.hlc.2023.02.011_bib38","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/mt.2008.171","article-title":"Self-complementary AAV vectors; advances and applications","volume":"16","author":"McCarty","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.hlc.2023.02.011_bib39","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/mt.2008.76","article-title":"Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection","volume":"16","author":"Zincarelli","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.hlc.2023.02.011_bib40","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ymthe.2019.03.012","article-title":"The future: in\u00a0vivo CAR T cell gene therapy","volume":"27","author":"Mhaidly","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/j.hlc.2023.02.011_bib41","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1021\/mp200589z","article-title":"Cell targeting peptide conjugation to siRNA polyplexes for effective gene silencing in cardiomyocytes","volume":"9","author":"Nam","year":"2012","journal-title":"Mol Pharm"},{"key":"10.1016\/j.hlc.2023.02.011_bib42","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1073\/pnas.0435906100","article-title":"Cell transfection in\u00a0vitro and in\u00a0vivo with nontoxic TAT peptide-liposome-DNA complexes","volume":"100","author":"Torchilin","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.hlc.2023.02.011_bib43","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/s41551-018-0227-9","article-title":"Targeting protein and peptide therapeutics to the heart via tannic acid modification","volume":"2","author":"Shin","year":"2018","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.hlc.2023.02.011_bib44","doi-asserted-by":"crossref","first-page":"5432","DOI":"10.1038\/s41467-020-19230-w","article-title":"Identification of a myotropic AAV by massively parallel in\u00a0vivo evaluation of barcoded capsid variants","volume":"11","author":"Weinmann","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.hlc.2023.02.011_bib45","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nbt.1599","article-title":"Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle","volume":"28","author":"Asokan","year":"2010","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.hlc.2023.02.011_bib46","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1038\/mt.2014.127","article-title":"Cardiac I-1c overexpression with reengineered AAV improves cardiac function in swine ischemic heart failure","volume":"22","author":"Ishikawa","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.hlc.2023.02.011_bib47","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/j.jacc.2017.08.013","article-title":"Protein phosphatase inhibitor-1 gene therapy in a swine model of nonischemic heart failure","volume":"70","author":"Watanabe","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hlc.2023.02.011_bib48","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1161\/CIRCRESAHA.120.315855","article-title":"Gene therapy for the heart lessons learned and future perspectives","volume":"126","author":"Cannata","year":"2020","journal-title":"Circ Res"},{"key":"10.1016\/j.hlc.2023.02.011_bib49","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","article-title":"Immune responses to viral gene therapy vectors","volume":"28","author":"Shirley","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.hlc.2023.02.011_bib50","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors","volume":"21","author":"Boutin","year":"2010","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.hlc.2023.02.011_bib51","doi-asserted-by":"crossref","first-page":"17158","DOI":"10.1073\/pnas.0909520106","article-title":"Distinct immune responses to transgene products from\u00a0rAAV1 and rAAV8 vectors","volume":"106","author":"Lu","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.hlc.2023.02.011_bib52","doi-asserted-by":"crossref","first-page":"670","DOI":"10.3389\/fimmu.2020.00670","article-title":"Human immune responses to adeno-associated virus (AAV) vectors","volume":"11","author":"Ronzitti","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.hlc.2023.02.011_bib53","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and\u00a0limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.hlc.2023.02.011_bib54","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nm1549","article-title":"CD8(+) T-cell responses to adeno-associated virus capsid in humans","volume":"13","author":"Mingozzi","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.hlc.2023.02.011_bib55","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/978-1-4939-6588-5_7","article-title":"Cell-based measurement of neutralizing antibodies against adeno-associated virus (AAV)","volume":"1521","author":"Jungmann","year":"2017","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.hlc.2023.02.011_bib56","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1258\/acb.2009.009077","article-title":"A\u00a0convenient enzyme-linked immunosorbent assay for rapid screening of anti-adeno-associated virus neutralizing antibodies","volume":"46","author":"Ito","year":"2009","journal-title":"Ann Clin Biochem"},{"key":"10.1016\/j.hlc.2023.02.011_bib57","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/978-1-61779-370-7_11","article-title":"Measuring immune responses to recombinant AAV gene transfer","volume":"807","author":"Martino","year":"2011","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.hlc.2023.02.011_bib58","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hlc.2023.02.011_bib59","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2174\/156652311796150354","article-title":"Immune responses to AAV in clinical trials","volume":"11","author":"Mingozzi","year":"2011","journal-title":"Curr Gene Ther"},{"key":"10.1016\/j.hlc.2023.02.011_bib60","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005795","article-title":"Overcoming preexisting humoral immunity to AAV using capsid decoys","volume":"5","author":"Mingozzi","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.hlc.2023.02.011_bib61","doi-asserted-by":"crossref","first-page":"9155","DOI":"10.1073\/pnas.1605146113","article-title":"Extracellular vesicles and viruses: Are they close relatives?","volume":"113","author":"Nolte-'t Hoen","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.hlc.2023.02.011_bib62","doi-asserted-by":"crossref","first-page":"7598","DOI":"10.1016\/j.biomaterials.2014.05.032","article-title":"Naturally enveloped AAV vectors for shielding neutralizing antibodies and robust gene delivery in\u00a0vivo","volume":"35","author":"Gyorgy","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.hlc.2023.02.011_bib63","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1038\/mt.2011.108","article-title":"A\u00a010 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8","volume":"19","author":"Monteilhet","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.hlc.2023.02.011_bib64","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.omtm.2020.01.004","article-title":"Successful transduction with AAV vectors after selective depletion of anti-AAV antibodies by immunoadsorption","volume":"16","author":"Orlowski","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.hlc.2023.02.011_bib65","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1056\/NEJMoa1612567","article-title":"IgG endopeptidase in highly sensitized patients undergoing transplantation","volume":"377","author":"Jordan","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hlc.2023.02.011_bib66","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-020-0911-7","article-title":"IgG-cleaving endopeptidase enables in\u00a0vivo gene therapy in the presence of anti-AAV neutralizing antibodies","volume":"26","author":"Leborgne","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.hlc.2023.02.011_bib67","doi-asserted-by":"crossref","first-page":"e139881","DOI":"10.1172\/jci.insight.139881","article-title":"Rescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading enzyme","volume":"5","author":"Elmore","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.hlc.2023.02.011_bib68","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a025924","article-title":"Inhibition of the mechanistic target of rapamycin (mTOR)\u2014rapamycin and beyond","volume":"6","author":"Lamming","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.hlc.2023.02.011_bib69","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1002\/art.38107","article-title":"Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response","volume":"65","author":"Melet","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.hlc.2023.02.011_bib70","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/rheumatology\/key428","article-title":"Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis","volume":"58","author":"Ramwadhdoebe","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.hlc.2023.02.011_bib71","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1038\/s41467-018-06621-3","article-title":"Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration","volume":"9","author":"Meliani","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.hlc.2023.02.011_bib72","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.658038","article-title":"Immunomodulation in administration of rAAV: preclinical and clinical adjuvant pharmacotherapies","volume":"12","author":"Chu","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.hlc.2023.02.011_bib73","first-page":"1","article-title":"Addressing high dose AAV toxicity\u2014'one and done' or 'slower and lower'?","author":"Kishimoto","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.hlc.2023.02.011_bib74","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.hlc.2018.03.005","article-title":"Adeno-associated virus gene therapy: translational progress and future prospects in the treatment of heart failure","volume":"27","author":"Bass-Stringer","year":"2018","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.hlc.2023.02.011_bib75","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.molmed.2020.11.006","article-title":"Permeability of the endothelial barrier: identifying and reconciling controversies","volume":"27","author":"Claesson-Welsh","year":"2021","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.hlc.2023.02.011_bib76","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/mt.2011.268","article-title":"Concomitant intravenous nitroglycerin with intracoronary delivery of AAV1.SERCA2a enhances gene transfer in porcine hearts","volume":"20","author":"Karakikes","year":"2012","journal-title":"Mol Ther"},{"key":"10.1016\/j.hlc.2023.02.011_bib77","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/sj.gt.3301614","article-title":"In\u00a0vivo myocardial gene transfer: optimization and evaluation of intracoronary gene delivery in\u00a0vivo","volume":"8","author":"Wright","year":"2001","journal-title":"Gene Ther"},{"key":"10.1016\/j.hlc.2023.02.011_bib78","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1089\/10430340050015329","article-title":"Highly efficient adenovirus-mediated gene transfer to cardiac myocytes after single-pass coronary delivery","volume":"11","author":"Logeart","year":"2000","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.hlc.2023.02.011_bib79","first-page":"612","article-title":"Comparative study of catheter-mediated gene transfer into heart","volume":"115","author":"Li","year":"2002","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.hlc.2023.02.011_bib80","first-page":"392","article-title":"Incomplete retention after direct myocardial injection","volume":"55","author":"Grossman","year":"2002","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.hlc.2023.02.011_bib81","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/sj.gt.3302793","article-title":"Three catheter-based strategies for cardiac delivery of therapeutic gelatin microspheres","volume":"13","author":"Hoshino","year":"2006","journal-title":"Gene Ther"},{"key":"10.1016\/j.hlc.2023.02.011_bib82","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.yjmcc.2007.02.004","article-title":"Targeted high-efficiency, homogeneous myocardial gene transfer","volume":"42","author":"Sasano","year":"2007","journal-title":"J\u00a0Mol Cell Cardiol"},{"key":"10.1016\/j.hlc.2023.02.011_bib83","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.jacc.2004.05.074","article-title":"Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins: comparison with surgical and percutaneous intramyocardial gene delivery","volume":"44","author":"Raake","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hlc.2023.02.011_bib84","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1089\/hgtb.2015.120","article-title":"Locally targeted cardiac gene delivery by AAV microbubble destruction in a large animal model","volume":"27","author":"Schlegel","year":"2016","journal-title":"Hum Gene Ther Methods"},{"key":"10.1016\/j.hlc.2023.02.011_bib85","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/gt.2010.168","article-title":"Myocardial gene delivery using molecular cardiac surgery with recombinant adeno-associated virus vectors in\u00a0vivo","volume":"18","author":"White","year":"2011","journal-title":"Gene Ther"},{"key":"10.1016\/j.hlc.2023.02.011_bib86","doi-asserted-by":"crossref","first-page":"8029","DOI":"10.1038\/s41598-019-43737-y","article-title":"A\u00a0normothermic ex\u00a0vivo organ perfusion delivery method for cardiac transplantation gene therapy","volume":"9","author":"Bishawi","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.hlc.2023.02.011_bib87","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/gt.2012.3","article-title":"Cardiac gene therapy in large animals: bridge from bench to bedside","volume":"19","author":"Ishikawa","year":"2012","journal-title":"Gene Ther"},{"key":"10.1016\/j.hlc.2023.02.011_bib88","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1152\/physiolgenomics.00032.2022","article-title":"Distribution of cardiomyocyte-selective adeno-associated virus serotype 9 vectors in swine following intracoronary and intravenous infusion","volume":"54","author":"Li","year":"2022","journal-title":"Physiol Genomics"},{"key":"10.1016\/j.hlc.2023.02.011_bib89","doi-asserted-by":"crossref","first-page":"H2995","DOI":"10.1152\/ajpheart.00703.2004","article-title":"Catheter-based antegrade intracoronary viral gene delivery with coronary venous blockade","volume":"288","author":"Hayase","year":"2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.hlc.2023.02.011_bib90","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S1525-0016(03)00149-7","article-title":"Catheter-based intracoronary myocardial adenoviral gene delivery: importance of intraluminal seal and infusion flow rate","volume":"8","author":"Emani","year":"2003","journal-title":"Mol Ther"},{"key":"10.1016\/j.hlc.2023.02.011_bib91","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1089\/10430340152528101","article-title":"How to optimize in\u00a0vivo gene transfer to cardiac myocytes: mechanical or pharmacological procedures?","volume":"12","author":"Logeart","year":"2001","journal-title":"Hum Gene Ther"}],"container-title":["Heart, Lung and Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950623001154?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950623001154?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T18:08:38Z","timestamp":1761415718000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1443950623001154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":91,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1443950623001154"],"URL":"https:\/\/doi.org\/10.1016\/j.hlc.2023.02.011","relation":{},"ISSN":["1443-9506"],"issn-type":[{"value":"1443-9506","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Barriers in Heart Failure Gene Therapy and Approaches to Overcome Them","name":"articletitle","label":"Article Title"},{"value":"Heart, Lung and Circulation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hlc.2023.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}